Cydexa – for dry eye relief

Today’s cyclodextrin is about cyclodextrins and nutraceuticals, a specific application in particular: Cydexa – for dry eye relief

The following is claimed for the product:
“the Entrocoat Cyclodextrin Autoencapsulation Technology significantly enhances the effectiveness of Cydexa. This innovative technology encases Cydexa probiotics in a protective cyclodextrin coat, ensuring their survival through the digestive system and maintaining their potency until they reach the small and large intestines. Once released by Entrocoat, the Cydexa probiotics are further enhanced by the cyclodextrin core, which acts as a prebiotic, thereby enhancing their effectiveness for optimal gut health and aiding dry eye relief.”

We have not tested this product yet, and while the above is possible with CDs, it is certainly challenging.
1. CDs usually cannot protect products in the digestive system on their own.
2. The release from the CD cavity is rather difficult to control or extend

We will do some testing soon and share what we find.

In any case, the product does look super sexy 🙂

Oculis closes Phase 3 eye drop trial due to ‘administrative error’ from third party

Today’s cyclodextrin is some news fresh from Oculis‘s oven about the lead drug OCS-01, which is delivered with a unique and proprietary cyclodextrin technology.

The company reported in its second-quarter financial filing that a Phase 3 trial for Oculis’ lead eye drop candidate will be shut down due to an administrative error.

The company added, however, that it had a pre-NDA meeting with the FDA this month, where it got the go-ahead to still file for approval in the first quarter of next year. According to Oculis, the agency confirmed the data it already has from its first Phase 3 trial and a Phase 2 trial, alongside safety data from other studies in ocular surgery and diabetic macular edema, are enough to support an NDA submission.

I’m so happy that this unfortunate event does not seem to hold back the progress of this amazing drug and technology.

If OCS-01 is approved, it would be the first daily and preservative-free steroid for treating inflammation and pain following ocular surgery.